Updated CINV Guidelines New Evidence for Change and Practical Issues
Making Progress in Controlling Emesis Efficacy and Effectiveness
Clinical Risk Factors for Emesis Personalizing Control
Evidence and Targets
Neurotransmitters and Antiemetic Pathways Targeting Key Pathways to Influence Emetic Control
Antiemetics in 2015 Practical Issues
NK1 RAs Approved* for Use as Antiemetics
Netupitant and NEPA
NEPA Phase 3 Trial Design
NEPA Phase 3 Trial CR Rates
DEX for Delayed Emesis Associated With 1 Dose of Cyclophosphamide or Anthracycline
Rolapitant A New NK1 RA
Rolapitant Phase 3 Trial Clinical Efficacy for Moderately Emetic Chemotherapy
Olanzapine as an Antiemetic Overview
Olanzapine 4-Agent (Including Cisplatin) Phase 2 Trial KCOG-G1301
Olanzapine 4-Agent Phase 3 Trial Alliance 221301
APR in Pediatrics, 2015 Phase 3 Randomized Trial; N = 302
Addition of APR in a 5-Day Cisplatin Trial Germ Cell Tumors
Benefit of NK1 RAs in Patients Receiving Carboplatin Phase 3 Trials
Perceptions and Reality Influence on Overuse and Underuse of Antiemetics
Two Studies Examining the Effectiveness of Guidelines Definitions
Adherence to NCCN Guidelines US Registry (INSPIRE) Study
Adherence to NCCN Guidelines US Registry (INSPIRE) Study: Results
Pan European Emesis Registry (PEER) Study Design Using MASCC Guidelines
Pan European Emesis Registry (PEER) Study Results Using MASCC Guidelines
Resource Use (Cycle 1) PEER Study Using MASCC Guidelines
Overview of Guidelines (NCCN/ASCO®/MASCC-ESMO) for Acute Nausea and Vomiting
Differences Among Guidelines ASCO®
Differences Among Guidelines NCCN and MASCC-ESMO
Recommendations for Refining Guidelines Acute Nausea and Vomiting
Recommendations for Refining Guidelines Delayed Nausea and Vomiting
Case 1 Breast Cancer
Case 2 Lung Cancer
Case 2 Lung Cancer (cont)
Case 2 Lung Cancer (cont)
Case 2: Antiemitic Options Lung Cancer (cont)
Improved Ability to Control Chemotherapy-Induced Emesis
Antiemetic Guidelines Conclusions
Multiple Roles for Supportive Care in Cancer
Abbreviations